Document is current
Any future updates will be listed below
-
Authors
Bruel, Timothée
Staropoli, Isabelle
Bay, Pierre
Bastard, Paul
Préau, Sébastien
Guigon, Aurélie
Guillon, Antoine
Stefic, Karl
Uhel, Fabrice
Pelleau, Stéphane
Garcia, Laura
Puel, Anne
Cobat, Aurélie
Casanova, Jean-Laurent
Pawlotsky, Jean-Michel
White, Michael
Schwartz, Olivier
Fourati, Slim
de Prost, Nicolas https://orcid.org/0000-0002-4833-4320
-
Funding
Funding for this research was provided by:
EMERGEN consortium—ANRS Maladies Infectieuses Emergentes (ANRS0153)
French Foundation for Medical Research (EA20170638020)
French national agency of research (ANR-23-CE15-0039-01)
- License Information
-
More Information
Article History
Received: 27 June 2025
Accepted: 17 November 2025
First Online: 26 November 2025
Declarations
:
: The study was approved by the Comité de Protection des Personnes Sud-Méditerranée I (N° EudraCT/ID-RCB: 2021-A02914-37). Informed consent was obtained from all patients or their relatives.
: Consent to publish has been obtained from patients or their relatives.
: S.F. has served as a speaker for GlaxoSmithKline, AstraZeneca, MSD, Pfizer, Cepheid and Moderna; J.-M.P. has served as an advisor or speaker for Abbvie, Arbutus, Assembly Biosciences, Gilead and Merck; N.D.P has served as an advisor or speaker for Moderna and AstraZeneca. T.B. has served as a speaker for AstraZeneca. Other authors and investigators have no conflict of interest to disclose.
